# EDGAR Filing Document

**Accession Number:** 0001921865
**File Stem:** 0001477932-23-001361
**Filing Date:** 2023-3
**Character Count:** 9599
**Document Hash:** 5b0ccad884a2efb6e3148b1d087e64cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-001361.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001477932-23-001361

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20230308

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASP Isotopes Inc.
- **CENTRAL INDEX KEY:** 0001921865
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS CHEMICAL PRODUCTS [2890]
- **IRS NUMBER:** 872618235
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41555
- **FILM NUMBER:** 23714869

**BUSINESS ADDRESS:**
- **STREET 1:** 433 PLAZA REAL, SUITE 275
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
- **BUSINESS PHONE:** (858) 677-1400

**MAIL ADDRESS:**
- **STREET 1:** 433 PLAZA REAL, SUITE 275
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432

?xml version="1.0" encoding="utf-8"?aspi_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 8, 2023**

---

| |
|:---|
| **ASP ISOTOPES INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware**  | **001-41555** | **87-2618235** |
| (State or other jurisdiction of<br>incorporation) | (Commission File Number) | (IRS Employer <br>Identification No.) |

---

---

| | |
|:---|:---|
| **433 Plaza Real, Suite 275. Boca Raton, FL** | **33432** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: <u>**(561) 709-3034**</u> 

 **<u>N/A</u>**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Ticker symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.01** | **ASPI** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

**Item 8.01 Other Events.**

On March 8, 2023, the Company issued a press release entitled "ASP Isotopes Set for Commercial Launch with Completion of first Isotopes Enrichment Facility." A copy of this press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](aspi_ex991.htm) | [Press Release dated March 8, 2023](aspi_ex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ASP ISOTOPES INC** | **ASP ISOTOPES INC** |
| Date: March 8, 2023 | By: | */s/ Paul Mann* |
|  | Name:  | Paul Mann |
|  | Title:  | Chief Executive Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**ASP Isotopes Set for Commercial Launch with Completion of first Isotopes Enrichment Facility**

ASP Isotopes Inc. NASDAQ: ASPI ("ASPI", the "Company", "us", "we" or "our"), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes for use in multiple industries, today announced that it has successfully concluded the construction and cold commissioning of its light isotope enrichment facility in Pretoria, South Africa. The Company achieved this milestone approximately three months faster than it originally anticipated.

The Company's new facility is currently operating and enriching isotopes in line with management's expectations, based on prior extensive R&D experiments conducted by ASPI and mathematical models. The Company previously entered into a Memorandum of Understanding with a North American customer for the entire production of its new facility. After the facility's initial processing of material to obtain the desired performance output, management expects the facility to generate initial revenues and cash flow during the later part of 2023.

"*The start-up of our first isotope enrichment facility is a major milestone for our company. We look forward to it entering commercial production later this year. I would like to thank all the employees who have worked extremely hard during the last 6 months to bring this facility to completion*" said Paul Mann, ASPI's Chairman and CEO.

Management believes that there is an urgent need for reliable and cost-efficient isotope suppliers, as many historically already fragile supply chains have been interrupted by current geopolitical events. The Company's facility is designed for the enrichment of isotopes with low molecular masses. Management believes that the plant has the capability to enrich products such as Silicon-28, Carbon-13 and Carbon-14 and Oxygen-18.

**About ASP Isotopes Inc.**

ASPI is an advanced materials company dedicated to the development of technology and processes designed to produce isotopes used in multiple industries. We have an exclusive license to use proprietary technology, the Aerodynamic Separation Process ("ASP technology") for the production, distribution, marketing and sale of all isotopes.

Our initial focus is on the production and commercialization of enriched Carbon-14, Silicon-28 and Molybdenum-100 ("Mo-100"), and we are constructing two commercial scale isotope enrichment plants in Pretoria, South Africa. We believe Silicon-28 has the potential use in advanced semiconductors and the quantum computing end markets, and Carbon-14, which has potential application in the pharma/agrochemical target end market. We believe that the Mo-100 we plan to develop using the our technology has significant potential advantages for use in the preparation of nuclear imaging agents by radiopharmacies and others in the medical industry.

In addition, we are considering future development of its facilities for the separation of Zinc-68, Ytterbium-176, Zinc-67, Nickel-64 and Xenon-136 for potential use in the healthcare target end market, and Uranium-235, Chlorine -37 and Lithium-6 for potential use in the nuclear energy target end market.

We are incorporated in Delaware in September 2021. Our principal executive offices are located at 433 Plaza Real, Suite 275, Boca Raton, Florida 33432, and our telephone number is (561) 709-3034. Our website address is <u>www.aspisotopes.com</u>.

**Forward Looking Statements**

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended and the Securities Litigation Reform Act of 1995. The Company may also make written or oral "forward-looking statements" in documents filed with the U.S. Securities and Exchange Commission, in press releases, in reports to stockholders and in other materials or communications describing the Company. These "forward-looking statements" involve a number of risks, uncertainties, assumptions and other factors, many of which are outside of the Company's control, that could cause actual results to differ materially from such statements. For a more detailed description of these risks, uncertainties, assumptions and other factors, please see the Company's filings with the Securities and Exchange Commission, (and in particular the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the Company's SEC filings). Readers are cautioned not to put undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date they are made, and we have no intention and undertake no obligation to update or revise any of them in light of new information, future events or otherwise. Copies of these documents are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

**Contacts**

Robert Ainscow – Interim Chief Financial Officer

<u>ir@aspisotopes.com</u>

Dave Gentry – RedChip

<u>dave@redchip.com</u>

2<br>